Rajaprabhakaran Rajarethinam is a Psychiatry physician. OpenAlex indexes 39 publications with 1,756 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3001 Plymouth Rd
Suite 107
Ann Arbor, MI 481053205
Telephone
734-846-2898Registry record last updated 13 Feb 2015.
Clinical trials
- Systematic Evaluation of Antiviral Medication in Schizophrenia
Sponsor: Konasale Prasad
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Neurocrine Biosciences, Inc.Program year202312 payments
- Janssen Pharmaceuticals, IncProgram year20213 payments
- LivaNova USA, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
97.3%Atypical Antipsychotic47.2%Clozapine29%Aripiprazole19%Olanzapine15%Quetiapine Fumarate12%Ziprasidone Hcl7%Asenapine Maleate7%Risperidone7%Clozapine Odt6%Part D<11 patientsTypical Antipsychotic10.6%Haloperidol75%Haloperidol Decanoate26%Part D<11 patients+ 9 more classes in this area
Cardiovascular
2.7%Beta blocker2.7%Propranolol Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 112. Effects of Ziprasidone Versus Placebo in Patients at Clinical High Risk for Psychosis
Schizophrenia Bulletin
2017 - Prescription stimulant use is associated with earlier onset of psychosis
Journal of Psychiatric Research
2015 - Early Intervention and the Treatment of Prodrome in Schizophrenia
Journal of Psychiatric Practice
2013 - Alterations in the cerebral white matter of genetic high risk offspring of patients with schizophrenia spectrum disorder
Progress in Neuro-Psychopharmacology and Biological Psychiatry
2012 - Early prodromal symptoms can predict future psychosis in familial high-risk youth
Journal of Psychiatric Research
2011
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”